Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology
- 12 April 2022
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 63, 103805
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy RegistryMultiple Sclerosis Journal, 2016
- Glatiramer acetate during early pregnancy: A prospective cohort studyMultiple Sclerosis Journal, 2016
- MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patientsNature Reviews Neurology, 2015
- Defining high, medium and low impact prognostic factors for developing multiple sclerosisBrain, 2015
- Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis CohortJAMA Neurology, 2015
- Influence of treatments in multiple sclerosis disability: A cohort studyMultiple Sclerosis Journal, 2014
- Natalizumab dosage suspension: Are we helping or hurting?Annals of Neurology, 2010
- Real‐life impact of early interferonβ therapy in relapsing multiple sclerosisAnnals of Neurology, 2009
- Measures in the first year of therapy predict the response to interferon β in MSMultiple Sclerosis Journal, 2009
- Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patientsMultiple Sclerosis Journal, 2008